VRd或达雷妥尤单抗为基础的四药联合方案改善原发性浆细胞白血病患者生存:希腊骨髓瘤研究组多中心研究
该多中心研究比较了硼替佐米-来那度胺三药联合(VRd)或达雷妥尤单抗为基础的四药联合方案(DBQ)与既往抗骨髓瘤治疗在原发性浆细胞白血病(pPCL)中的疗效,纳入110例患者,结果显示VRd/DBQ与更高的完全缓解率、更长的无进展生存期和总生存期相关。
要点
- VRd/DBQ治疗与更高的完全缓解率相关(41% vs 17%,p=0.008)。
- VRd/DBQ组中位无进展生存期25个月,显著长于BSC/CT组的13个月(p=0.03)。
- VRd/DBQ组中位总生存期未达到,显著长于BSC/CT组的20个月(p<0.001)。
核心结论
- 在真实世界环境中,VRd/DBQ治疗可诱导深度且持久的缓解,是总生存期的强预后因素,目前为pPCL的最佳治疗选择。
研究设计与样本
- 多中心研究,纳入2001年至2021年间注册的3324例骨髓瘤患者中的110例原发性浆细胞白血病患者(占3%),其中37%循环浆细胞为5%-19%。
- 患者中位年龄65岁(范围44-86),男性51例、女性59例;89%接受新型联合方案,包括DBQ(21%)、VRd(16%)和BSC(52%);35%接受自体干细胞移植。
主要发现
- 83%的患者获得客观缓解;VRd/DBQ治疗与更高的完全缓解率强烈相关(41% vs 17%,p=0.008)。
- 中位随访51个月(95%CI:45-56)后,67例患者死亡,早期死亡率为3.5%。
- 中位无进展生存期为16个月(95%CI:12-19.8),VRd/DBQ组显著长于BSC/CT组(25个月,95%CI:13.5-36.5 vs 13个月,95%CI:9-16.8;p=0.03)。
- 中位总生存期为29个月(95%CI:19.6-38.3),VRd/DBQ组未达到,显著长于BSC/CT组的20个月(95%CI:14-26);3年总生存率分别为70% vs 32%(p<0.001;HzR:3.88)。
临床怎么用
- 作者认为,VRd/DBQ治疗是pPCL目前的最佳治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We evaluated the efficacy and prognostic impact of bortezomib-lenalidomide triplet (VRd) or daratumumab-based quadruplets (DBQ) versus previous anti-myeloma therapies, that is, bortezomib standard combinations (BSC) or conventional chemotherapy (CT), in a large cohort of patients with primary plasma cell leukemia (pPCL), including those fulfilling the revised diagnostic criteria, that is, circulating plasma cells (cPCS): ≥5%; 110 pPCL patients (M/F: 51/59; median age 65 years, range: 44-86) out of 3324 myeloma patients (3%), registered in our database between 2001 and 2021, were studied; 37% had cPCS 5%-19%; 89% received novel combinations including DBQ (21%), VRd (16%) and BSC (52%); 35% underwent autologous stem cell transplantation. 83% achieved objective responses. Treatment with VRd/DBQ strongly correlated with a higher complete response rate (41% vs. 17%; p = .008). After a median follow-up of 51 months (95% CI: 45-56), 67 patients died. Early mortality was 3.5%. Progression-free survival was 16 months (95% CI: 12-19.8), significantly longer in patients treated with VRd/DBQ versus BSC/CT (25 months, 95% CI: 13.5-36.5 vs. 13 months 95% CI: 9-16.8; p = .03). Median overall survival (OS) was 29 months (95% CI: 19.6-38.3), significantly longer in patients treated with VRd/DBQ versus BSC/CT (not reached vs. 20 months, 95% CI: 14-26; 3-year OS: 70% vs. 32%, respectively; p < .001; HzR: 3.88). In the multivariate analysis VRd/DBQ therapy, del17p(+) and PLT <100.000/μL, independently predicted OS (p < .05). Our study has demonstrated that in the real-world setting, treatment with VRd/DBQ induces deep and durable responses and is a strong prognostic factor for OS representing currently the best therapeutic option for pPCL.
引用
- Katodritou E, Kastritis E, Dalampira D, et al. Improved survival of patients with primary plasma cell leukemia with VRd or daratumumab-based quadruplets: A multicenter study by the Greek myeloma study group. Am J Hematol. 2023. PMID: 36869876. doi:10.1002/ajh.26891
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。